Lexington, MA – According to filings with the U.S. Securities and Exchange Commission, Alloy Therapeutics is raising $74,999,875.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Errik Anderson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Alloy Therapeutics

Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners, we democratize access to tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics. We provide affordable, non-exclusive access to the entire drug discovery community from academic scientists, small and medium biotech, to the largest biopharma. Our lead offering, the ATX-Gx platform, is a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Founded in 2017 and privately funded by visionary investors, we are headquartered in Boston, MA with European labs in Cambridge, UK. As a reflection of our relentless commitment to the scientific community, Alloy reinvests 100% of its revenue in innovation and access to innovation.

To learn more about Alloy Therapeutics, visit http://www.alloytx.com/

Contact:
Errik Anderson, Chief Executive Officer
617-203-7111
errik.anderson@alloytx.com
https://www.linkedin.com/in/errikanderson/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved